AZ faces hit after Pulmicort patent ruling
This article was originally published in Scrip
Executive Summary
AstraZeneca is anticipating a significant hit to royalties received on sales of Teva's generic version of Pulmicort Respules (budesonide) after a US lower court ruled that one patent protecting the drug was invalid and that another had not been infringed by generic defendants involved in the litigation.